# COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

> **NCT04534725** · PHASE3 · COMPLETED · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 441 (actual)

## Conditions studied

- Cancer
- Covid19
- Respiratory Viral Infection

## Interventions

- **DRUG:** Interferon alfa
- **DRUG:** Selinexor
- **DRUG:** Lenzilumab

## Key facts

- **NCT ID:** NCT04534725
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2022-11-28
- **Final completion:** 2023-04-19
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534725, "COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04534725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*